SUBJECT INDEX

A

Acetaminophen
  interactions with phenobarbital, 466
Acetylcholinesterase
  in sweat glands, 432
Acetylcysteine
  and kidney stone dissolution, 364, 366
N-Acetyl-(L-cysteine (Mucomyst®)
  in kidney stone dissolution, 364
Acetylsalicylic acid
  and glucose-induced insulin secretion, 8–10
Acne
  androgen-related hormonal treatment of, 491, 497
Acquired immunodeficiency syndrome (AIDS)
  and dermatologic infections, 211
Acromegaly
  and pituitary hormones, 283, 287–90, 292
ACTH
  see Adrenocorticotrophin hormone
Acute lymphocytic leukemia (ALL)
  and antibody treatment, 110, 112, 114
Acute myocardial infarction
  see Myocardial infarction
Acyclovir
  and dermatologic infections in compromised host, 211–12
Addison's disease
  and abnormal sweating, 446
Adenine arabinoside
  in infection therapy for compromised hosts, 212
Adenoma
  colorectal
    and cancer risk, 503–4, 509, 513–14
Adenosine triphosphate (ATP)
  and pseudohypoparathyroidism, 259, 261
Adenylate cyclase
  in Graves' disease, 271
  role in cAMP synthesis
    and pseudohypoparathyroidism, 259–61
Adolescence
  depressive disorder in, 232, 236
  iron deficiency in, 63
Adrenal steroids
  as chemotherapeutic agents
    and cognitive defects, 39–40
  and renin release
    in congestive heart failure, 171
Adrenocorticotrophin hormone (ACTH)
  and angiotensin system
    in congestive heart failure, 171
  and growth hormone deficiency, 535
  and onset of Graves' disease, 278
  and pituitary tumor management, 284, 291–92
Adriamycin
  side effects of, 40
Albright's hereditary osteodystrophy
  and pseudohypoparathyroidism, 259–64
Alcohol
  interactions with cannabis, 256
Alcohol consumption
  and coronary heart disease, 189
Alcoholism risk
  and depressive disorder, 237
Aldosterone
  and angiotension
    in congestive heart failure, 171, 173, 175
  role in sweating disorders, 446–47
Allergic diseases
  and sweating disorders, 441
Alloantibody diseases
  and plasma exchange therapy, 80, 83–84
Amenorrhea
  and prolactin-secreting tumors, 285
Amino acids
  in sweat composition, 445
Amino acid sequence
  of human growth hormone, 521
γ-Aminobutyric acid (GABA)
  role in febrile seizures, 455
Aminoglycoside
  in infection therapy for compromised hosts, 213
Amodiaquine
  and drug-resistant malaria, 325
Amotivation
  and cannabis use, 251
Amoxicillin
  in gonorrhea treatment, 342–43, 353
Amphetamines
  and cannabis interactions, 256
Ampicillin
  in endocarditis treatment, 422
  in gonorrhea treatment, 342–43, 353
Amyloidosis
  and sweat gland abnormalities, 432
Anderson-Fabry disease
  and sweat gland abnormalities, 432, 442–43
Anemia
  and iron absorption, 62
  in renal therapy, 29
  transfusion-dependent
    and hemapheresis, 72–73
Aneurysms
  surgical removal of
    and evoked potential use, 485
  surgical treatment of
    see Subarachnoid hemorrhage
Angiotensin II
  role in congestive heart failure
    see Congestive heart failure
Anhidrosis
  treatment of, 441–44
    congenital abnormalities, 444
    neural lesions, 441–43
    physical damage, 443–44
Anhidrotic ectodermal dysplasia
  and sweating disorders, 444
Animal studies
  of insulin resistance, 153–54
Antibiotic resistance
  and urethral infection treatment, 338–39
Antibiotics
  in malaria treatment, 328–30

Antibiotic treatment
of endocarditis
see Endocarditis
Antibodies
as complement system
and infections, 47–52
and immunoregulation in
bowel disease
see Inflammatory bowel
disease
to insulin
and insulin resistance, 151
tumor therapy with
see Tumor therapy
see also Immune response;
Immunoglobulin;
Immunological events
Anticoagulants
and prosthetic valve
endocarditis, 426
and postphlebitic syndrome
94, 101
and subarachnoid
hemorrhage therapy, 372
Anticonvulsant action
of cannabis, 257
Anticonvulsants
in aneurysm treatment,
371
in febrile seizure therapy,
464–67
Antidepressant drug therapy
in childhood depressive
disorder, 240–41
in treating delirium, 42
Antidiuretic hormone (ADH)
and renin release
in congestive heart failure,
171
resistance to
and pseudohypopara-
thyroidism, 261
Antiemetics
in cancer
and cognitive deficits, 41
Antifibrinolytic agents
and subarachnoid
hemorrhage therapy,
372–73
Antigenic modulation
in tumor therapy with
antibodies, 111
Antigens
and cell markers
in leukemia and
lymphoma, 118–28
in complement system
and infections, 48–52
histocompatibility
and kidney transplant
survival, 134–37
role in transplant rejection,
26–27
tumor specific
see Tumor therapy
see also Antibodies;
Autoimmune; Immune
response;
Immunoglobulin
Antiidiotype antibody
and tumor therapy, 113
Antilymphocyte antibodies
in inflammatory bowel
disease, 197
Antilymphocyte globulin
as antirejection therapy
in kidney transplants, 27,
31
Antiperspirants
and anhidrosis, 443
Antipyretics
in febrile seizure therapy,
462, 466–67
Antirejection therapy
in kidney transplants, 27,
31–32
Antisocial personality
and depressive disorder, 237
Antithrombin III
deficiency of
and phlebitis, 93–94, 96,
99
Antrum
role in gastric emptying,
220–24
Anxiety
in parents of febrile seizure
patients, 464–65
as side effect
of cannabis use, 250
Apathy
as side effect
of cannabis use, 251
Apheresis
see Hemapheresis
Arginine
and insulin response
in diabetes mellitus, 17
Arachidonic acid metabolism
and diabetes mellitus, 2–4
Arteriosclerosis
see Atherosclerosis
Arteriovenous malformations
surgical treatment of
see Subarachnoid
hemorrhage
Arthritis
and gonococcal infections,
341, 346
see also Sexually acquired
reactive arthritis
Ascorbic acid
role in iron absorption,
57–59, 66
Aspergillosis
as marijuana contaminant,
254
Aspirin
chronic use of
and iron deficiency, 64
Asthma
cannabis therapy for, 257
Atherosclerosis
coronary
in diabetics, 162, 164–65
effects of exercise training
on, 402–3, 406
and right ventricular
infarction, 378–79
role of diet in, 179–92
alcohol consumption, 189
carbohydrates, 182–83,
186–88
cholesterol, 182–86
clinical trials, 183
discussion, 190–92
epidemiological evidence,
181
experimental studies, 183
fat, 181–82, 186–88
fiber, 188–89
and healthy population,
191–92
hyperlipidemia and
vascular disease, 191
protein, 182–83, 188
summary, 192
Atropine
and cannabis interactions,
256
Auditory evoked potentials
see Brainstem auditory
evoked potentials
Auriculotemporal syndrome
and gustatory sweating, 439
Autoimmune disease
Graves' disease as, 267–78
and plasma exchange
therapy, 80–83
Autoimmune processes
as cause of diabetes mellitus,
1, 13–18
Autoimmune response
see Immunological events
Autoimmune symptoms
of insulin resistance, 156–57
5-Azacytidine (ARA-C)
side effects of, 40
Azathioprene
as antirejection therapy
in kidney transplants, 27,
31

B

Babesiosis
erythrocytapheresis in, 77

Bacteria
as cause of endocarditis, 422–26
Bacterial infections
dermatological
in compromised host, 209–10, 213–16
nosocomial spread of
vs viral infections, 313
Barbiturate poisoning
and sweat gland damage, 434
Barbiturates
and cannabis effects, 256
Barium enema
and colorectal cancer screening, 510
BCNU
side effects of, 40
Behavioral disturbances
in delirium classification, 37
Behavioral effects
of cannabis, 251–52, 255
Benzodiazepines
in treating delirium, 42
Biochemistry
of growth hormone variants
see Growth hormone
Biofeedback
and sweating treatment, 438
Biopsy
and colorectal cancer screening, 511
Birth defects
and cannabis, 255
Blacks
and type B insulin resistance syndrome, 156
Bleomycin
side effects of, 40
Blood cultures
in endocarditis diagnosis, 414–18
in febrile seizure management, 463
Blood group
as predisposing factor in phlebitis, 95
Blood loss
and iron deficiency, 64
Blood pressure
effects of exercise on
and coronary heart disease, 393, 397, 402, 404–6
regulation of
and congestive heart failure, 170, 172
Blood testing
fecal occult
and cancer screening, 506–9, 512–13
Blood transfusions
and iron overload, 64
and kidney transplant survival, 138–40
see also Hemapheresis
Bone disease
in children
and renal therapy, 25, 29
Bone marrow transplant
and dermatologic infection risk, 212
and monoclonal antibody therapy, 113–14
Bowel disease
immunoregulation in
see Inflammatory bowel disease, 195–201
Bradykinin
and angiotensin suppression, 174
Brain death
and evoked potentials, 484
Brainstem auditory evoked potentials (BAEP)
clinical applications of, 480–84
Bran
as iron absorption inhibitor, 59–60
Bromocryptine therapy
for abnormal sweating, 440
in pituitary tumor management, 286–90, 292
BUN levels
and renal failure in children, 22, 31
Burn patients
and anhidrosis, 443

C

C1–C9
see Complement system
cAMP
see Cyclic adenosinemonophosphate
Calcium
in pseudohypoparathyroidism, 260, 262–64
role in gastric emptying, 225
role in sweating, 434–35
Calcium balance
in renal failure therapy, 22–24
Calcium deposits
and sweat gland abnormalities, 433
Calcium transport
in diabetes
and heart failure, 165–66
Caloric intake
and renal failure in children, 22–23
Cancer
antibody therapy for
see Tumor therapy
colorectal
see Colorectal cancer
see Carcinoma
Cancer chemotherapies
nausea effects
cannabis therapy, 256
Cancer patients
cognitive defects in
and chemotherapy
see Cognitive defects
and dermatophyte infection risk, 212
Candida
as cause of endocarditis, 424–25
risk to compromised hosts, 215–16
Cannabis, 247–57
amotivation, 251
behavioral effects, 251–52
birth defects and teratogenicity, 255
cardiovascular system, 252
cellular toxicity and carcinogenicity, 254
drug interactions, 256
effects on nervous system, 250–52
gastrointestinal effects, 254
immune system, 255
introduction, 247
pharmacology and chemistry, 248–49
psychiatric effects, 250–51
reproductive function, 255–56
respiratory system, 253–54
therapeutic uses, 256–57
Captopril
in congestive heart failure treatment, 174–75
Carbohydrate intolerance
and Type A syndrome of insulin resistance, 157
Carbohydrates
dietary
and coronary heart disease, 182–83, 186–88
and gastric emptying rates, 225
Carbon monoxide poisoning
and sweat gland damage, 434
Carcinoembryonic antigen
and colorectal cancer screening, 512
Carcinogenicity
of marijuana, 254
Carcinoma

and chronic wart disease, 210
patient history of
and risk of colorectal cancer, 503–5, 509, 514
Cardiac rehabilitation
and exercise, 401–3
Cardiovascular disease
and diabetes
see Heart failure
myocardial infarction
see Right ventricular infarction
role of diet in
see Atherosclerosis
Cardiovascular effects
of cannabis, 252
Catecholamine levels
and aneurysm treatment, 372, 374
Catecholamines
and ACTH secretion, 284
and cannabis effects on heart, 252
as insulin antagonists, 151
and renin release
in congestive heart failure, 171–72
Cell markers in leukemia and lymphoma, 117–28
biological significance of identification, 126–27
diagnostic and prognostic significance, 127–28
hematopoietic cell differentiation, 118–20
identifying markers, 120–21
immunophenotypes, 121–24
labeling and analysis, 121
phenotypes of non-Hodgkin's lymphoma, 124–26
reagents, 120–21
types of samples, 120
Cell-mediated immune mechanisms
in type I diabetes mellitus, 15–16
Cellular toxicity
of marijuana, 254
Central nervous system
and cancer side effects
cognitive defects, 38–40
Central nervous system lesions
location with evoked potentials, 483
Cephalosporin
in endocarditis treatment, 421–22
Cerebrospinal fluid
abnormalities in
and febrile seizures, 455–56
CH_{50}
and complement measurement, 52
Chagas' disease
and gastric emptying, 221
Chemolysis
of kidney stones
see Kidney stones
Chemotaxins
role in complement system, 49–51
Chemotherapeutic agents
and cognitive defects in cancer patients, 37–44
Chemotherapy
and cognitive defects
see Cognitive defects
Child Depression Rating Scale (CDRS)
in assessing depressive disorder, 233
Childhood acute lymphoblastic leukemia (Childhood ALL)
and cell marker identification, 120–22, 124, 127
Childhood leukemia
cognitive defects in
from chemotherapy, 37, 39
Children
depressive disorder in
see Depressive disorder
diabetes diagnosis
recommendations for, 307
febrile seizures in, 453–67
growth hormone deficiency in, 527, 535–36, 540
iron needs of, 56, 63
progressive renal failure in, 21–32
respiratory syncytial virus in, 312–18
Chlamydia trachomatis
in urethral infections, 337, 342, 344–50, 352–53
Chlorguanide
in malaria treatment, 327
Chlorimipramine
and cannabis interactions, 256
Chloroquine
as antimalarial treatment, 321–31
Chlorpromazine
as cause of hyperprolactinemia, 285
Cholesterol
dietary
and atherosclerosis, 182–86
Cholinergic stimulation
of sweat glands, 434–35
Chronic lymphocytic leukemia (CLL)
and antibody treatment, 113
and hemapheretic therapy, 76
Citric acid
role in iron absorption, 59
Clindamycin
in malaria treatment, 330
in urethritis treatment, 347
Clinical trials
of cancer chemotherapy
and cognitive defects, 35–36
of the lipid hypothesis
in coronary heart disease, 183
of monoclonal antibodies
table of, 109
Clonidine
in treating gustatory sweating, 440
Cocaine
and cannabis interactions, 256
Cochlear lesions
and abnormal BAEPs, 481–82
Cognitive Capacity Screening Examination
in cancer therapy, 41
Cognitive defects
assessment of
using evoked potential, 485
in cancer patients, 35–44
case reports, 43–44
delirium, 38–39
disorders of cognitive function, 36–37
introduction, 35–36
mental status examinations, 41–42
related to chemotherapy, 39–40
resulting from cancer itself, 40–41
resulting from concurrently administered medications, 41
treatment of delirium, 42
of chronic phenobarbital therapy, 466–67
Cold agglutinin disease (CAD)
and plasma exchange therapy, 82
Coliform infection
and urethritis, 350–54
Colitis
history of
and colorectal cancer risk, 503, 505–6

see Inflammatory bowel disease
Collaborative Perinatal Project (NCPP)
and febrile seizure studies, 456–58, 460–62
Colonoscopy
and colorectal cancer screening, 510–13
see also Proctosigmoidoscopy; Sigmoidoscopy
Colorectal cancer, 501–15
asymptomatic patients, 512–14
barium enema, 510
biopsy, 511
carcinoembryonic antigen, 512
colonoscopy, 510–11
cytology, 511–12
fecal occult blood testing, 506–8
groups at risk, 503–6
polypectomy, 511
proctosigmoidoscopy, 508
screening measures, 506–12
sigmoidoscopy, 508–10
symptomatic patients, 515
Coma
and evoked potential analysis, 484
Common acute lymphoblastic leukemia antigen (CALLA)
as cell marker, 119–20, 122, 124–27
and tumor therapy with antibodies, 111, 114
Complement receptors (C3)
and cell markers, 119
Complement system
and infections, 47–52
biologically active products, 48–49
complement measurements, 51–52
deficiencies, 50–51
host defenses, 49–50
pathways of complement activation, 48
Compliance
with cancer therapy
and mental status examination, 41
Computer models
and transplant success prediction, 141
Concanavalin-A-inducible suppression
and immunoregulation in bowel disease, 198, 201
Congenital heart disease
and risk of nosocomial RSV, 317
Congestive heart failure
and angiotensin suppression, 169–76
angiotensin-converting enzyme inhibitors, 174–75
captopril, 174–75
cardiovascular and renin-angiotensin regulation, 170–71
conclusions, 176
pathophysiology and treatment, 171–73
saralasin, 173–74
teprotide, 174
and antithrombic treatment, 95
in diabetics
see Heart failure
Continuous ambulatory peritoneal dialysis (CAPD)
of children, 24
Continuous cycling peritoneal dialysis (CCPD)
of children, 24
Contraceptive agents
hormonal agonists as, 491–92, 494–96
Convulsions
see Febrile seizures
Corneal lesions
and visual evoked potentials, 478
Coronary artery disease
in diabetics, 162–63
Coronary heart disease
and exercise
see Exercise
and impaired glucose tolerance, 304
role of diet in
see Atherosclerosis
Corpus luteum
hormone agonist effects on, 493–94, 496
Corticosteroids
and sweating disorders, 448
Corticosteroid therapy
and risk of dermatologic infection, 208, 210, 212
Corticotrophin-releasing factor (CRF)
and ACTH secretion, 284, 292
Cortisol
as insulin antagonist, 151
interactions with phenobarbital, 466
secretion
and depressive disorder, 237–38
Corynebacterium sp.
as cause of endocarditis, 424–25
Coumarin
as anticoagulant, 94
Cranial nerves
and application of somatosensory evoked potentials, 479
Creatinine
in transplant rejection, 27, 29–30
Crohn's disease
immunoregulation in, 196–98, 201
and plasma exchange therapy, 80
and risk of colorectal cancer, 506, 514
see also Inflammatory bowel disease
Cryoglobulinemia
and plasma exchange therapy, 79–81, 85
Cryptococcal infection
in compromised hosts, 214–15
CT scanning (computerized tomography)
and diagnosis of subarachnoid hemorrhage, 368–70, 373–74
CU32-085 (Sandoz)
and growth hormone suppression, 288
Cushing's disease
and pituitary tumor management, 291–92
and sweating disorders, 448
Cytology
and colorectal cancer screening, 511–12
Cytomegalovirus
and febrile seizure studies, 459
3',5',-cyclic Adenosine monophosphate (cAMP)
in Graves' disease, 271, 275–76
and pseudohypoparathyroidism, 259–61, 264
role in insulin secretion, 5–6
Cyclooxygenase pathway
and prostaglandins in diabetes mellitus, 2–6

Cyclophosphamide
and cognitive defects, 39–40, 43
Cysteine
role in iron absorption, 59
Cystic fibrosis
and sweating disorder, 436, 446–47
Cystine calculi
percutaneous dissolution of, 364–66
Cystitis
and urethritis, 349–51
Cytapheresis
see Hemapheresis
Cytosine arabinoside
side effects of, 40
Cytotoxicity
and immunoregulation in bowel disease, 195–96, 200–1
of marijuana, 254

D

Dapsone
in malaria treatment, 327
Danuorubicin
side effects of, 40
Defense mechanisms
against disease
see Complement system
and compromised host
see Dermatologic infections
Dehydration
and sweating, 434
Delirium
in cancer patients, 36–44
Delusions
in childhood depressive disorder, 236
Dementia
with arteriovenous malformations, 368
in cancer patients, 36–37
Deoxynucleotidyl terminal transferase (TdT)
and cell marker identification, 119–21, 124
Depression
as behavioral response of delirium
in cancer patient, 43–44
exercise effects on, 402
Depressive disorder
in childhood, 231–42
cortisol secretion, 237–38
depressive mood assessment, 234–36
diagnosis and assessment, 231
familial aggregation, 237
growth hormone secretion, 238–39
psychobiology, 236–40
psychosocial interventions, 241–42
sleep studies, 239–40
treatment, 240–42
Depressive drugs
and cannabis interactions, 256
Dermatologic infections
in compromised host, 205–16
classification of infection, 209–16
dermatophyte infection, 212
disseminated infection, 212–15
fungal, 214–15
mycosis, 213–16
opportunistic primary skin infection, 215–16
primary skin infection, 209–10, 215–16
pseudomonas, 213
skin as infection barrier, 207–9
unusually widespread infection, 210–12
viral infection, 210–12
Dermatology
sweating disorders
see Sweating
Dermatomyosis
and plasma exchange therapy, 80, 84
Dermatophyte infection
in compromised hosts, 212
Desmethylimipramine
in childhood depression treatment, 240
Dexamethasone
interactions with phenobarbital, 466
Dexamethasone suppression test (DST)
for depressive disorder, 238
Diabetes
classification and diagnosis, 295–308
diagnostic criteria, 300
distinction between IDDM and NIDDM, 303–4
interpreting the OGTT, 302–3
new classification, 298–99
oral glucose tolerance test (OGTT), 300–2, 305–7
table of categories, 299
type I and type II, 299, 303
exercise effects on, 405
and gastric emptying, 221
Diabetes mellitus
classification and diagnosis
see Diabetes
classification tables for, 299, 302
and glucose homeostasis
role of prostaglandins in, 1–11
and heart failure, 164
and plasma exchange therapy, 80, 83
and sweating disorders, 440–41, 443
type I
autoimmune components, 13–18
type II
and insulin resistance, 153–57
Diabetics
congestive heart failure in
see Heart failure
Diagnosis
of childhood depressive disorder, 231–42
see also specific diseases
Diagnostic and Statistical Manual III
see DSM-III
Dialysis
and transplant
in renal failure therapy, 24–25
Diarrhea
persistent syndrome of babies and diabetes mellitus type I, 18
Diazepam
in febrile seizure management, 462, 466–67
poisoning
and sweat gland damage, 434
Diet
and atherosclerosis, 179–92
as factor in postphlebitic syndrome, 95
Digestive system
mechanisms and disorders
see Gastric emptying
Digitalis
in congestive heart failure therapy, 169
and heart failure in diabetes, 166
Disease mechanisms
and insulin resistance
see Insulin receptors
Disorders
of cognitive function
see Cognitive defects
Diuretics

in congestive heart failure treatment, 169, 172
DNA (deoxyribonucleic acid)
and genetic basis of growth hormone synthesis, 522–23, 531–33, 541–42
Donors
of kidneys
and renal therapy for children, 26, 30
L-Dopa (levo-Dihydroxyphenalanine)
and ACTH secretion, 284, 288
Dopamine
and growth hormone regulation, 284–86, 289–90
Doppler ultrasound
see Ultrasound
Doxycycline
in malaria treatment, 328–29
in urethritis treatment, 347, 353
Drug
dependence
see Cannabis
interactions
with cannabis, 256
with phenobarbital, 466
research
and malaria resistance
see Falciparum malaria
DSM-III (Diagnostic and Statistical Manual)
and assessment criteria of childhood depression, 232
and classification of cognitive disorders, 36–37
DTIC
side effects of, 40
Duodenum
and gastric emptying, 220–26
Dwarfism
and growth hormone deficiency, 535–36
Dysautonomia
and sweating disorders, 441

E

Edema
in phlebitis, 95
Elderly
gastric emptying and metabolism, 224
institutionalized
respiratory syncytial virus among, 314
Electroencephalogram (EEG)
and febrile seizures, 454–55, 457, 463–64
Electrolyte balance
and renal failure in children, 22
Electrolyte disturbances
following subarachnoid hemorrhage, 372
Electrolytes
in sweat composition, 445, 448
Electroretinogram (ERG)
and visual evoked potentials, 476
Emotional sweating, 437–39
Enalapril
see MK-421
Endocarditis
antibiotic treatment of, 413–26
bacterial causes, 422–26
enterococci, 420–21
gram-negative bacilli, 422
management, 415–18
microbiology lab in diagnosis, 414–15
penicillin-sensitive streptococci, 418–20
prosthetic valve endocarditis, 426
staphylococci, 422–23
Endocrine disorders
prolonged autoimmune processes in, 16–18
Endocrine glands
and diabetes mellitus type I, 16–17
Endocrinology
see Gonadotropin-releasing hormone agonists; Growth hormone; Hyperthyroidism; Insulin receptors; Pituitary tumors; Pseudohypoparathyroidism
Endometriosis
hormonal treatment of, 491, 497–98
Endorphins
and mood change after exercise, 403
Endothelial-monocyte antigens
and kidney transplants, 137–38
Energy transfer
and gastric emptying, 224
Enterococci
as cause of endocarditis, 416, 420–21
Environmental disease
arteriosclerosis as, 190
Enzyme markers
in identification of T cells, 118
Enzymes
in sweat composition, 445
in sweat glands, 432, 435
Epidemiology
of respiratory syncytial virus
see Respiratory syncytial virus
of urethral infections
see Urethral infections
Epilepsy
and febrile seizures, 456–60, 463–64, 466–67
Erythrocytapheresis
applications of, 77
Erythrocyte rosette methods
for cell marker identification
in leukemia and lymphoma, 120–22
Erythrocytosis
and antithrombic treatment, 95–96
Erythropoiesis
and iron absorption, 62
Estrogens
and childhood depressive disorder, 238
as predisposing factor in phlebitis, 95
and renin release
in congestive heart failure, 171
Estrogen secretion
effects of hormonal agonists on, 496
Ethical problems
in renal therapy for children, 25–26
Ethylenediamine tetraacetic acid (EDTA)
as iron absorption inhibitor, 60
Evoked potentials
clinical applications
see Sensory evoked potentials
Exercise
and coronary heart disease, 391–407
amount and type of exercise, 399
cardiac rehabilitation, 401–3
cardiovascular response to exercise, 403–4
effects on risk factors, 404–6
introduction, 391–92
primary prevention, 392–94
prospective studies, 395–98
retrospective studies, 394–95
summary, 406–7

survival after myocardial infarction, 399–403
and depression, 402
Experimental febrile seizures, 456
Eye
visual evoked potentials
clinical applications, 474–78

F

Falciparum malaria
drug therapy, 321–31
amodiaquine, 325
antibiotics, 328–30
assessing parasite susceptibility, 322–24
chloroquine alternatives, 324
new antimalarial drugs, 330–31
quinine and quinidine, 324–25
sulfonamide-pyrimethamine, 325–26
sulfone-antifolate drug combinations, 327
erythrocytapheresis in, 77
Familial aggregation
and depressive disorder, 237
Family studies
of diabetes mellitus patients
see Heritability
Fansidar®
in malaria treatment, 322, 326, 328–29, 331
Fat
dietary
and atherosclerosis, 180–82, 186–88
and gastric emptying rates, 226
Febrile seizures, 453–67
anticonvulsant treatment, 464–67
cerebrospinal fluid
biochemical findings, 455–56
clinical characteristics, 454
epilepsy, 457–60
experimental febrile seizures, 456
genetics, 454–55
intellectual outcome, 461
management, 462–64
motor handicap, 461–62
partial complex seizures, 460–61
pathophysiology, 455–56
recurrences, 456–57
Fecal occult blood testing
as screening for cancer, 506–9, 512–13
Feedback mechanisms
and coronary heart disease, 185, 190
Fenwal CS3000
and hemapheretic technology, 71
Fever
seizures during
see Febrile seizures
Fiber
dietary
and coronary heart disease, 188–89
as iron absorption inhibitor, 59–60
Fiberoptic sigmoidoscopy
and cancer screening, 508–10
Fibrinolysis
and postphlebitic syndrome, 96, 98, 100
Flashback
and cannabis use, 251
Fluorochromes
in labeling and analysis of cell markers, 121
Fluorouracil
side effects of, 40
Follicle-stimulating hormone (FSH)
and superactive agonists, 492–98
and tumor management, 284
Frank-Starling mechanism
and angiotensin system
in congestive heart failure, 172
Frey's Syndrome
and gustatory sweating, 439
Ftorafur
side effects of, 40
Fundus
role in gastric emptying, 220–22
Fungal infections
dermatological
in compromised host, 209, 213–16

G

GABA
see γ-Aminobutyric acid
GM Gangliosidosis
and sweat gland abnormalities, 432
Gardner's syndrome
and risk of colorectal cancer, 504
Gastric emptying
and cannabis use, 254
mechanisms and disorders of, 219–26
antrum and pylorus, 222–23
changes in duodenal receptivity, 223
duodenal receptors, 224–26
energy transfer, 224
fragmentation of food, 224
fundus and antrum, 220
mechanical events of emptying, 221–23
role of stomach in metabolism, 219–20
stomach as a pump, 220–21
transmembrane potential, 221
Gastrointestinal effects
of cannabis use, 254
Genetic disorders
of bioinactive growth hormone, 540–42
hemochromatosis
and iron absorption, 65–66
see also Pseudohypoparathyroidism
Genetic markers
for Graves' disease, 271
see also Cell markers
Genetic predisposition
to Graves' disease, 269–71, 277–78
Genetics
and growth hormone variants
see Growth hormone
role in febrile seizures, 454–55
see also Heritability
Gentamicin
in treating endocarditis, 413, 416, 420, 422, 424–25
Gestational diabetes
diagnosis and classification of, 299
Glaucoma
cannabis therapy for, 257
Glucagon
as insulin antagonist, 151
secretion of
effects of prostaglandins on, 1, 4, 6–7
Glucocorticoids
impact on prostaglandin synthesis, 4
Glucose
in sweat composition, 445
Glucose homeostasis
role of prostaglandins in and diabetes mellitus, 1–11
Glucose intolerance
in agromegaly, 289

Glucose metabolism
and gastric emptying, 219–20, 225
and insulin action, 146–48
Glucose tolerance
and diabetes classification
see Diabetes
and exercise
in diabetics, 405
Glucose tolerance test
and diabetes diagnosis and classification, 296–97, 300–2
criteria for interpretation, 302–3
indications for, 305–7
Gonadotropin-releasing hormone agonists
superactive, 491–98
see also Follical-stimulating hormone; Leutinizing hormone
Gonadotropins
resistance to
and pseudohypoparathyroidism, 261
Gonococcal arthritis-dermatitis syndrome
and C5 deficiency, 51
Gonorrhea, 337–44
clinical manifestations, 340–41
diagnosis, 341–42
transmission, 339–41
treatment, 342–43
vaccine, 343–44
see also Urethral infections
Goodpasture's syndrome
and plasma exchange therapy, 80, 82–83
Grafts
see Transplants
Graft survival
of kidney transplants in children, 25
Gram-negative bacilli
as cause of endocarditis, 422
Granulocytes
separation of
and hemapheresis, 72
Graves' disease
and hyperthyroidism, 267–78
and plasma exchange therapy, 80, 83
Growth
as problem in renal failure in children, 21–32
Growth hormone (hGH)
abnormalities of
and depressive disorder, 238–39
and heart failure in diabetics, 165
as insulin antagonist, 151
regulation
and pituitary tumor management, 283–84, 287–90, 292
structural variants of, 519–43
bioassays of, 523
bioinactivity, 535–37
charge variants of, 524–27, 538–39
genetic basis of hGH synthesis, 532–35
heritable alterations, 534–35
implications and conclusions, 537–42
introduction, 520–24
mass variants, 527–31, 538–39
Guanosine triphosphate (GTP)
role in pseudohypoparathyroidism, 260–61
Guillain-Barre syndrome
and plasma exchange therapy, 80, 83
Gustatory sweating
treatment of, 439–40
Gut associated lymphoid tissue (GALT)
and immunologic observations in bowel disease, 196

H

Haemonetics Model 30
and hemapheretic technology, 71
Hairy cell leukemia
and leukapheretic therapy, 76
Hallucinations
in childhood depressive disorder, 236
Haloperidol
as cause of hyperprolactinemia, 285
in delirium treatment, 42
Handwashing
as infection control procedure, 317
Hashimoto's thyroiditis
and Graves' disease, 268–70, 273
Headache
as warning of aneurysm, 368–69
Heart disease
see Atherosclerosis; Endocarditis; Right ventricular infarction
Heart failure
and angiotensin suppression
see Congestive heart failure
in diabetics, 161–66
congestive heart failure, 164–65
intramural vessels, 163
management, 166
pathogenesis, 165–66
subclinical cardiomyopathy, 163–64
and postphlebitic syndrome, 95–96
Heat dissipation
by sweating, 430, 440–41, 444
Heat stroke
and anhidrosis, 441–42
Hemapheresis, 69–86
apheresis, 71–74
diseases treated by plasma exchange, 80–85
technology, 70–71
terminology, 70
therapeutic cytapheresis, 74–77
therapeutic plasma exchange, 77–85
Hematology
complement measurement and infection, 52
see also Cell markers; Hemapheresis; Iron absorption; Postphlebitic syndrome; Tumor therapy
Hematopoietic cell differentiation
markers of
in leukemia and lymphoma, 118–20
Heme
see Iron absorption
Hemoccult® slide
and cancer screening, 506–7, 510
Hemochromatosis
idiopathic
and iron absorption, 65–66
Hemodialysis
in children, 24, 26
Hemodynamics
and postphlebitic syndrome 92–93, 96–98, 102
of right ventricular infarction, 380–83
(Rh) Hemolytic disease of the newborn (HDN)
and plasma exchange therapy, 80, 84

Heparin
as anticoagulant, 94, 101–2
Hepatic enzyme metabolism
and cannabis inhibition, 256
Heritability
of diabetes mellitus type I, 13–18
of febrile seizures, 454–55
of pseudohypoparathyroidism, 259–64
Herpes simplex virus
and dysuria in women, 351
and infection risk
for compromised hosts, 211
Hexamethylmelamine
side effects of, 40
Hirsutism
hormonal treatment of, 491, 497
Histamine release
and products of complement activation, 48
Histocompatibility antigens
and kidney transplants, 133–38
see also HLA
HLA antigens (Human leukocyte antigens, group A)
in kidney transplant survival, 133–37, 142
and suitable kidney donors, 26
HLA-B27
and susceptibility to sexually acquired arthritis, 346
HLA-DR antigens
as cell markers, 119, 122
HLA-linked gene
and iron absorption, 55, 65–66
HLA tissue typing
and predisposition to diabetes mellitus, 13–17
Hodgkin's disease
and dermatologic infection risk, 212
Hookworm infestation
and iron deficiency, 64
Hormonal antagonists
of insulin action
and insulin resistance, 151–52
Hormonal interactions
as cause of diabetes mellitus, 1
Hormones
and glandular tumors
see Pituitary tumors
superactive agonists
see Gonadotropin-releasing hormone agonists
variants of growth hormone
see Growth hormone
Hospitals
spread of respiratory syncytial virus in, 311–18
Hot flushes
and hyperhidrosis, 440–41
Human chorionic somatomammotropin
and growth hormone gene structure, 532
Human leukocyte antigen (HLA) DRW-3
in Graves' disease, 270–71, 274, 277
see also HLA
Human leukocyte interferon
in infection therapy
for compromised hosts, 212
Human lymphocyte antigen (HLA)
and insulin-dependent diabetes, 297–98
see also HLA
Hunter's syndrome
and sweating disorders, 448
Hurler's syndrome
and sweating disorders, 448
Hybridomas
lymphocyte
see Tumor therapy
Hydration
and renal failure in children, 22
Hydrocephalus
following subarachnoid hemorrhage, 372–73
5-Hydroxytryptamine
see Serotonin
Hyperandrogenism
and insulin resistance, 158
Hypercalcemia
and delirium
in cancer, 44
Hypercholesterolemia
as coronary risk factor
and exercise, 393, 397–98, 404–6
in diabetics, 162
Hypereosinophilic syndromes
use of leukapheresis in, 76
Hyperglycemia
chronic
and diabetes diagnosis and classification, 295–96, 298
and heart failure in diabetics, 166
role of prostaglandins in, 6, 9
Hyperhidrosis
see Sweating
Hyperinsulinemia
and insulin resistance studies, 153–54
Hyperlipidemia
role of diet in
see Atherosclerosis
Hyperparathyroidism
prophylaxis against
in renal failure therapy, 22, 24, 28
and pseudohypoparathyroidism, 263
Hyperphosphatemia
in pseudohypoparathyroidism, 260
treatment of
in renal failure therapy, 24
Hyperprolactinemia
treatment of, 283, 285, 288
Hypertension
and aneurysm therapy, 371
as coronary risk factor
and exercise, 393, 397, 402, 404–6
in diabetics, 162
Hyperthermia
drug-induced
and sweat gland damage, 434
Hyperthyroidism
pathogenesis of, 267–78
autoimmunity, 268–69
basis for altered immunity, 277–78
genetic predisposition, 269–71
Graves' hyperthyroidism, 271–72
human thyroid-stimulating activity, 272–77
Hyperviscosity syndrome
and plasma exchange therapy, 79, 81
Hypnosedatives
and cognitive deficits in cancer, 41
Hypocalcemia
in pseudohypoparathyroidism, 260, 262, 264
Hypocomplementemia
and infections
see Complement system
Hypogammaglobulinemia
and inherited absence of C3, 50
Hypoglycemia
and childhood depressive disorder, 238

and insulin receptor studies, 149, 157
role of prostaglandins in, 7
Hypogonadotropic hypogonadism
hormonal treatment of, 498
Hypothalamic disturbance
and aneurysm therapy, 372
Hypothyroidism
and sweating disorders, 447
Hysteria
and evoked potential analysis, 484

I

Iatrogenic complications
in endocarditis, 415
see also Dermatologic infections; Cognitive defects; Respiratory syncytial virus
IBM 2997
and hemapheretic technology, 71
Ibuprofen
and glucose-induced insulin secretion, 8
Ig
see Antibodies; Antigens; Immunoglobulin
Imipramine
in childhood depression treatment, 240–42
Immune complexes
and plasma exchange therapy, 80, 84–85
Immune reactions
and febrile seizures, 455
Immune response
in bowel disease, 195–201
Immunization
of children
and febrile seizures, 454
Immunoactivity
of growth hormone, 529, 541–42
Immunodeficiency diseases
and dermatologic infection, 211–12
Immunofluorescence
in cell marker identification, 121–22
Immunoglobulin antibodies (IgG)
in infection defense, 49, 51
in tumor therapy, 108
Immunoglobulin antibodies (IgM)
in tumor therapy, 108
Immunoglobulins (Ig)
and cell markers
in leukemia and lymphoma, 118–19, 123, 126
in complement system, 49
of Graves' disease patients
and hyperthyroidism, 267–78
in inflammatory bowel disease, 197, 199–201
Immunological events
leading to diabetes mellitus type I, 13–18
cell-mediated immune mechanisms, 15–16
gut endocrine related antibodies, 17
humoral autoimmune responses, 14–15
other endocrine glands and pathogenesis, 16–17
prolonged latency, 16
Immunological factors
in kidney transplants
see Kidney transplant survival
Immunology
and compromised host
see Dermatologic infections
Immunophenotypes
of lymphoid leukemias, 121–24
Immunoreactivity
of growth hormone, 536–37
Immunoregulation
in bowel disease
see Inflammatory bowel disease
Immunosuppression
as cannabis effect, 255
induction by lymphocytapheresis, 76, 79
Immunosuppressive therapy
and dermatologic infection, 207–16
see Dermatologic infections
in kidney transplants, 25, 27–28, 31–32, 133–34
and plasma exchange therapy, 79, 85
and risk of nosocomial RSV, 317–18
Impaired glucose tolerance
and diabetes classification and diagnosis
see Diabetes
Indomethacin
and glucose homeostasis, 4–6, 8
Infants
iron deficiency in, 63
rate of gastric emptying and metabolism, 224
respiratory syncytial virus in nosocomial spread, 312–18
Infection control
and nosocomial spread of RSV, 317–18
see Respiratory syncytial virus
Infections
damage to vessels
and postphlebitic syndrome, 97
during cancer
and cognitive defects, 39, 41
and hypocomplementemia
see Complement system
recurrent
and complement measurement, 51–52
see also Dermatologic infections; Respiratory syncytial virus; Urethral infections; and specific pathogens
Infertility
idiopathic
hormonal treatment of, 498
Inflammatory bowel disease
and endocarditis, 418
immunoregulation in, 195–201
antilymphocyte antibodies, 197
cell-mediated immunity, 197–98
etiology and pathogenesis, 196
humoral immunity, 197
immunologic observations, 196–97
intestinal mucosal mononuclear cells, 199–201
peripheral blood studies, 198
and risk of colorectal cancer, 505–6
Insulin
and diabetes classification and diagnosis, 296–97
see also Diabetes; Diabetes mellitus
Insulin-dependent diabetes mellitus (IDDM)
diagnosis and classification, 299, 303
Insulin hypoglycemia
and growth hormone immune reaction, 536

Insulin-like growth factors (IGFs)
and insulin receptors, 146, 148
Insulin receptors
and insulin resistance, 145–58
abnormal insulin, 150–51
antibodies to insulin, 151
hormonal antagonists, 151–52
insulin action, 146–48
and obesity, 152–54
prereceptor antagonists, 151–52
receptors, 146–48
resistance, 148–50
syndromes of extreme resistance, 156–58
and type II diabetes, 153–56
Insulin secretion
effects of prostaglandins on, 1–11
and gastric emptying, 220
Interferon
and regulation of NK-K cells, 199
side effects of, 40
International Atherosclerosis Project
and diet and coronary heart disease, 181
International Workshop Study of kidney transplants
and histocompatibility, 136–38
Interpersonal relationships
and intervention in childhood depression, 241–42
Interviewing
and assessment of depressive disorder, 233–34
Interview Schedule for Children (ISC)
and depressive disorder assessment, 233
Intestinal absorption
and gastric emptying
see Gastric emptying
Iontophoresis
as sweating therapy, 439
Iron absorption, 55–66
bioavailability of food iron, 56–60
control of, 62–63
disturbances of iron balance, 63–66
iron deficiency, 63–64
iron overload, 64–66
ligand effects, 59–60
mucosal transport, 60–61
Islet-cell antibodies (ICA)
as diabetes mellitus type I markers, 14–18
Isophosphamide
side effects of, 40

K

Kanamycin
in subarachnoid hemorrhage therapy, 374
Katz Adjustment Scale
and assessment of depression and anxiety
in exercise studies, 402
Ketoacidosis
and heart failure in diabetics, 165–66
Ketoconazole
in infection therapy
for compromised hosts,212
Kidney
see Renal failure
Kidney stones
percutaneous dissolution, 359–66
calcium oxalate, 366
cystine, 364–66
magnesium-ammonium-phosphate calculi, 361–63
technique, 360–61
uric acid calculi, 363–64
Kidney transplant survival
immunological factors in, 133–42
histocompatibility antigens—HLA, 134–37
non-HLA histocompatibility antigens, 137–38
pretransplant blood transfusions, 138–40
retransplants, 140–41
Kininase II
suppression of, 173–74

L

Lactic acid
role in iron absorption, 59, 64
L-Dopa
see Dopa
Leisure time activity
and exercise
in CHD studies, 397
Leprechaunism
and insulin resistance, 158
Lergotrile
and growth hormone suppression, 388
Leucocyte migration inhibition
and diabetes mellitus type I, 15
Leukapheresis
in management of myelegenous leukemia, 75–76
Leukemia
B-cell
and tumor therapy with antibodies, 113
T-cell
and tumor therapy with antibodies, 110–12, 114
cell marker identification in
see Cell markers
myelogenous
and hemapheretic therapy, 75–76
and risk of pseudomonas infection, 213
see also Acute lymphocytic leukemia; Childhood acute lymphoblastic leukemia; Chronic lymphocytic leukemia
Leukotrienes
as products of cyclooxygenase pathway
in diabetes mellitus, 3–4
Leuprolide
in prostate cancer therapy, 493
Levonantradol
therapeutic use of, 256
Lifestyle
as predisposing factor
in postphlebitic syndrome, 95
Ligands
effects on iron absorption, 59–60
Lipid hypothesis
in atherosclerosis etiology, 180, 183
Lipid solubility
of cannabis, 248–49
Lipoatrophic diabetes
and insulin resistance, 158
Liposclerosis
in postphlebitic syndrome, 95, 98, 101–2
Lisuride
and growth hormone suppression, 288, 290
Lithium
in cancer therapy
and cognitive deficits, 41
Lupus erythematosus
see Systemic lupus erythematosus
Luteinizing hormone (LH)
and cannabis effects on reproduction, 255

and superactive agonists, 492–98
and tumor management, 284
Lymph node irradiation
as antirejection therapy
in kidney transplants, 32
Lymphocyte hybridomas
see Tumor therapy
Lymphocytes
harvesting via apheresis, 73, 76
B Lymphocytes
and cell markers
in leukemia and lymphoma, 118–19, 124–26, 128
and histocompatibility matching—HLA, 136–37
T Lymphocytes
and cell markers
in leukemia and lymphoma, 118–19, 122–28
Lymphocyte transformation tests
and diabetes mellitus type I, 15–16
Lymphocytotoxic antibodies
and kidney graft survival, 139, 141
Lymphoma
cell marker identification in
see Cell markers

M

Malaria
see Falciparum malaria
Malic acid
role in iron absorption, 59
Malnutrition
and renal therapy in children, 25
Maloprim®
in malarial treatment, 327
Mania
and depressive disorder, 237
Marijuana
see Cannabis
Markers
for childhood depressive disorders, 238–39
see also Cell markers
Maudsley Family Inventory
in childhood depression intervention, 241
Mefloquine
in malaria treatment, 330–31
Memory disorders
assessment of, 42
Men
coronary heart disease in, 182
iron needs of, 64
Meningitis
and febrile seizure studies, 453, 461–63
Meningococcal meningitis
and C5 deficiency, 51
Mental illnesses
and sweating disorders, 448
Mental retardation
and febrile seizures, 461
Mental status examination
importance of
for cancer patients, 41–42
Metabolic control
in renal failure therapy, 23–24, 28
Metabolism
role of stomach in, 219–26
Metergoline
and growth hormone suppression, 288
Methotrexate
and cognitive disorders, 37, 39
Methyl dopa
as cause of hyperprolactinemia, 285
Metoclopramide
and gastric disorders, 221
Mini Mental State test
in cancer therapy, 41
Miliaria
and anhidrosis, 443
Minocycline
in malaria treatment, 328–29
in urethritis treatment, 347
Minnesota Multiphasic Personality Inventory (MMPI)
and depression assessment
in exercise studies, 402
MK-421 (Enalapril)
in congestive heart failure treatment, 175–76
Monamine oxidase
in sweat glands, 432
Monoclonal antibodies
and cell markers
in lymphoma and leukemia, 118, 120–22, 128
and immunoregulation in bowel disease, 195, 199
in tumor therapy
see Tumor therapy
Monocyte function
in bowel disease, 199
Monocyte-macrophage system
and immunoregulation in bowel disease, 195
Mononuclear cells
intestinal mucosal
in bowel disease, 199–201
Mood
changes
and exercise, 402–3
depressive
assessment of, 234–36
Motor handicap
and febrile seizures, 461–62
Mucopolysaccharidoses
and sweat gland abnormalities, 432, 447–48
Mucosal transport
of iron, 60–61
Multiple sclerosis
and abnormal sweating, 442
and evoked potentials in diagnosis, 483–84
and plasma exchange therapy, 80, 83
Mushroom poisoning
and plasma exchange therapy, 81
Myasthenia gravis
antibody analysis in, 15
and Graves' disease, 268
and plasma exchange therapy, 80, 83
Mycotic infection
risk for compromised hosts, 213–16
Myocardial infarction
acute
and antithrombic treatment, 94–95
and exercise effects, 391–407
see also Exercise
see Right ventricular infarction
Myocardial scans
and diagnosis of right ventricular infarction, 384
Myxedema
autoimmune processes in, 17–18

N

Nabilone
therapeutic use of, 256
Nafcillin
in endocarditis therapy, 413, 416, 422, 424
α-Naphthyl acetate esterase
in identifying T cells, 118–19
Narcotic analgesics
in cancer
and cognitive defects, 41
National Diabetes Data Group

diagnosis criteria, 295–96, 298, 301–5, 307–8
Neisseria gonorrhoeae
in urethral infections, 337–44, 349–50, 352–53
Neisseria sp.
as cause of endocarditis, 422, 424–25
Nelson's syndrome
and cyproheptadine treatment, 292
Neocytes
separation of
and hemapheresis, 72–73
Nephrology
pediatric
see Renal failure
Neurosurgery
use of evoked potentials during, 484–85
Neurotoxic effects
of chemotherapy agents
see Cognitive defects
Neurotransmitters
in cerebrospinal fluid
and febrile seizure studies, 455–56
role in sweating, 434–35
Neurotransmitter therapy
for Cushing's disease, 291–92
Neutropenia
and inherited absence of C3, 50
Nicotine
and cannabis effects, 256
Ni Hon-San Study
of coronary heart disease
in Japanese men, 182
Nitrogen mustard
side effects of, 40
NK-K cell system
and immunoregulation in bowel disease, 195, 198–201
Nocardial infection
risk for compromised hosts, 214
Non-Hodgkin's lymphoma
and dermatologic infection risk, 212
selected phenotypes of, 124–26
Non-insulin-dependent type diabetes mellitus (NIDDM)
diagnosis and classification, 299, 303
Nonsteroidal antiinflammatory drugs (NSAID)
and prostaglandin inhibition, 4–9
Noradrenaline
and growth hormone regulation, 284
Nortriptyline
in prepubertal major depression, 241

O

Obesity
as coronary risk factor
and exercise, 393, 404–5
and diabetes classification, 296–97, 299, 304
and diet
in cardiovascular disease, 180
and insulin resistance, 152–53, 155, 157–58
as predisposition to phlebitis, 95
Occlusion
of coronary arteries
in diabetes, 162
Occlusive dressings
and dermatologic infection risk, 216
Occupation
and exercise
in CHD studies, 394–96
Oldfield's syndrome
and risk of colorectal cancer, 504
Opiates
and cannabis interactions, 256
Opsonin (C3b)
role in infection, 49–51
Oral glucose tolerance test (OGTT)
see Glucose tolerance test
Organ damage
and cognitive defects
from chemotherapy, 40
Organic mental disorders
in DSM-III
and cancer patients, 36–37
Oslo Heart Study
of diet and coronary heart disease, 183
Osteoarthritis
in acromegaly, 287
Ovarian disease
polycystic
hormonal treatment of, 491, 497
Oxacillin
in endocarditis therapy, 413, 422, 424

P

Pancreas
see Diabetes mellitus
Pancreatitis
and sweating disorders, 446–47
Panhypopituitarism
and sweating disorders, 446
Panic
as side effect
of cannabis use, 250
Paranoia
as side effect
of cannabis use, 250
Paraquat poisoning
and cannabis
health effects, 253–54
and plasma exchange therapy, 81
Parathyroid hormone
role in pseudohypoparathyroidism, 260–64
Parkinson's disease
and abnormal sweating, 442
Pediatrics
management of progressive renal failure
see Renal failure
use of evoked potentials in, 485
Peer relations
of childhood depressives, 241–42
Pemphigus vulgaris
and plasma exchange therapy, 80, 83
Penicillin
in infection therapy
for compromised hosts, 213
resistance to
and urethral infections, 337–54
Penicillin G
in endocarditis therapy, 416, 418–20
in gonorrhea treatment, 342–43
Penicillinase-producing bacteria
in endocarditis, 416, 422
in urethal infections, 337–39, 343
Peptide hormones
biochemical and structural variants
see Growth hormone
Perceptual alterations
and cannabis use, 251
Perceptual disorders
assessment of, 42
using evoked potentials, 485
in delirium classification, 37
Percutaneous nephrostomy
see Kidney stones
Pergolide

and growth hormone suppression, 288
Pernicious anemia
and Graves' disease, 268
Peripheral blood studies
in bowel disease
and immunoregulation, 198–99
Peutz-Jeghers syndrome
and risk of colorectal cancer, 504
PGE
see Prostaglandins
pH
role in iron absorption, 58–61, 64
Phagocytic leukocytes
in complement system and infections, 47–52
Pharmacologic agents
in reproduction
see Gonadotropin-releasing hormone agonists
Pharmacology
of cannabis, 248–49, 256
Phencyclidine
and cannabis interactions, 256
Phenobarbital
interaction with cannabis, 256
in prophylaxis of febrile seizures, 465–67
side effects, 466–67
Phenothiazines
as cause of hyperprolactinemia, 285
Phlebitis
see Postphlebitic syndrome
Phosphorus balance
in renal failure therapy, 22–24
Photophobia
as warning of aneurysm, 368–69
Phototoxic reactions
from tetracyclines
and malarial treatment, 329
Phytohemaglutinin-P (PHA-P)
and immunoregulation in bowel disease, 201
Piribedil
and growth hormone suppression, 288
Pituitary gland
and diabetes mellitus type I, 16
growth hormone
structural variants of, 519–43
Pituitary tumors
surgical removal of
and evoked potential use, 485
treatment of, 283–92
acromegaly, 287–90
bromocriptine therapy, 290–91
Cushing's disease, 291–92
physiology, 284
prolactinomas, 285–87
Plasma
harvesting via apheresis, 73–74
Plasma exchange
therapeutic, 77–85
complications, 79
diseases treated by, 79–85
physiology of, 78–79
see also Hemapheresis
Plasminogen activator
and regulation of NK-K cells, 199
Plasmodium falciparum
multidrug-resistant strains
see Falciparum malaria
Platelets
and therapeutic cytapheresis, 71, 74–75
cis-Platinum
side effects of, 40
Play interviews
as assessment technique
and childhood depression, 233
Plethysmographic tests
in thrombosis and phlebitis, 99–100
Pneumonia
in infants and young children
nosocomial spread of, 311, 313, 317–18
Polyacrylamide gel electrophoresis (PAGE)
in growth hormone studies, 522, 525–27, 538–39, 542
Polyarteritis nodosa
and plasma exchange therapy, 80, 84
Polypectomy
and colorectal cancer screening, 511
Polyposis syndromes
history of
and colorectal cancer risk, 504–5
Polysomnography
see Sleep studies
Postphlebitic syndrome, 91–103
anatomy, 92
clinical syndromes, 94–95
hemostatic mechanism, 93–94
investigation, 98–100
management, 100–1
pathophysiologic considerations, 95–98
physiology, 92–93
Posttransfusion purpura (PTP)
and plasma exchange therapy, 80, 84
Potassium
intake
and renal failure in children, 22–24
and renin release
in congestive heart failure, 171
role in sweating, 437, 448
Precocious puberty
hormonal treatment of, 491–92, 497–98
Prednisone
as antirejection therapy
in kidney transplants, 27–28, 31
and cognitive defects, 39
Pregnancy
cannabis use during
and effects on infants, 255
glucose tolerance during
and diabetes diagnosis, 297, 299, 303, 305
iron needs during, 64
and malaria
need for safe drugs, 322, 326, 329–30
Prepubertal major depression
see Depressive disorder
Prevention
of infection
in compromised host
see Dermatologic infections
of coronary heart disease
exercise studies, 392–94
Procarbazine
side effects of, 40
Proctitis
see Inflammatory bowel disease
Proctosigmoidoscopy
and cancer screening, 508
Progesterone formation
and hormone agonists, 493–94, 496
Proguanil
in malaria treatment, 323, 327
Prolactin
bioactive variants of, 537–38
secretion
and pituitary tumor management, 283–88, 292
Propantheline
and sweating treatment, 438

Prostacyclin (PGI_2)
in diabetes mellitus, 2–3
and postphlebitic syndrome, 96–97
Prostaglandins
and regulation of NK-K cells, 199
role in glucose homeostasis and diabetes mellitus, 1–11
Prostate cancer
hormonal treatment of, 491–93, 496, 498
Prosthetic valve endocarditis
antimicrobial therapy for, 416, 426
Protein
abnormal blood
and plasma exchange therapy, 79–81
dietary
and atherosclerosis, 181–83, 188
and gastric emptying rates, 225–26
in sweat composition, 445
N-Protein
role in 260–61, 263–64
Pseudohypoparathyroidism
heritability of, 259–64
approach to patient, 263–64
associated endocrinologic abnormalities, 261
genetics, 263
phenotypic variability, 261–63
Pseudomonas aeruginosa
and dermatologic infection in compromised host, 213
Pseudo-pseudohypoparathyroidism (PPHP)
variant syndrome, 262
Psoriatic skin
and sweat gland abnormalities, 433, 443
Psychiatric effects
of cannabis use, 250–51
Psychiatry
child
see Depressive disorder; Cognitive Defects; DSM-III
Psychobiology
of prepubertal major depression, 236–40
Psychological effects
of exercise
and heart disease, 402–3
Psychological needs
and renal failure in children, 22–23, 25
Psychopharmacology
of childhood depressive disorder, 240–41
Psychoses
cannabis-induced, 250–51
Psychosocial growth
in children with progressive renal failure, 21, 27
Psychosocial interventions
in childhood depressive disorder, 241–42
Puberty
abnormal sweating during, 437
Pulmonary hemorrhage
and plasma exchange therapy, 83
Pylorus
role in gastric emptying, 222–23
Pyrimethamine
in malaria treatment, 322, 325–27

Q

Qinghaosu
in malaria treatment, 331
Quinidine
malarial resistance to, 324–25
Quinine
malarial resistance to, 322–25, 328

R

Radioimmunosassay (RIA)
in growth hormone studies, 519, 526–27, 529–30, 534–37, 542
and hormone measurement, 283
Radioisotopic studies
in thrombosis and phlebitis, 99
Radiotherapy
in subarachnoid hemorrhage, 371
Reactivity
lack of
and depressive mood assessment, 235–36
Rectal examination
as screening for cancer, 506
Rehabilitation
in progressive renal failure, 25, 27, 32
Reiter's syndrome
and urethritis, 346
Rejection
of transplant
and renal failure in children, 27–28, 30–32
Renacidin
in kidney stone dissolution, 359, 361
Renal calculi
see Kidney stones
Renal failure
progressive in children, 21–32
aims of treatment, 23
dialysis and transplant, 24–25
ethical problems, 25–26
growth, 27–28
immunological problems, 27
metabolic control, 23–24
rehabilitation, 32
technical problems, 26–27
therapeutic regime, 30–32
timing of treatment, 28–30
Renal transplant
in children, 24–31
dermatologic infection in, 207–16
rejection
and plasma exchange therapy, 80, 84
see also Kidney transplant survival
Rénin-angiotensin system
regulation of
and congestive heart failure, 170–71
Reproductive system
cannabis effects on, 255–56
Reserpine
as cause of hyperprolactinemia, 285
in subarachnoid hemorrhage therapy, 374
Respiratory complications
following subarachnoid hemorrhage, 372
Respiratory effects
of cannabis, 252–54
Respiratory syncytial virus
nosocomial spread of, 311–18
Rheumatoid arthritis
and plasma exchange therapy, 76, 80, 84–85
Rickets
and renal therapy in children, 24, 28
Rifampin
in endocarditis therapy, 416
in urethritis treatment, 347
Right ventricular infarction
diagnosis and management, 377–88
clinical features, 383
diagnosis, 383–84
hemodynamics, 380–83
management and treatment, 384–86
pathogenesis 378–80

pathology, 378
prognosis, 386–88
Risk
of colorectal cancer, 503–6
Risk factors
in coronary heart disease
and exercise studies, 393–94
RNA (Ribonucleic acid)
and genetic basis of growth hormone synthesis, 531–34, 542

S

Salivary glands
and gustatory sweating, 439
Salmonellosis
and marijuana use, 254
Salt
and sweat composition, 445–48
see Sodium chloride
Saralasin
and angiotensin suppression, 173–74
Schedule for Affective Disorders and Schizophrenia (K-SADS-P)
and depressive disorder assessment, 233
Schizophrenia
and depressive disorder, 237
Schizophrenics
and sweating disorders, 448
Screening
for colorectal cancer
see Colorectal cancer
Seizures
during fever
see Febrile seizures
Sensory evoked potentials, 473–85
brainstem auditory evoked potentials (BAEP), 480–83
somatosensory evoked potentials (SEP), 478–80
specific applications, 483–85
visual evoked potentials (VEP), 474–78
Sensory impairment
assessment of
and sensory evoked potentials, 483
Separation anxiety
and depressive mood assessment, 235
Sepis
see Dermatologic infection
Serotonin
(5-Hydroxytryptamine)
and growth hormone regulation, 284, 290
Seven-Country Study
of diet and coronary heart disease, 181
Sexually acquired reactive arthritis
and urethritis, 346
Short stature
and growth hormone deficiency, 535–36, 540
Sickle cell disease
erythocytapheresis in, 77
Sigmoidoscopy
flexible fiberoptic
and cancer screening, 508–10, 512–14
Skin
as infection barrier, 207–9
Skin changes
in postphlebitic syndrome, 95, 101
Sleep studies
of childhood depressives, 239–40
Sleep-wakefulness cycle
disturbances of
in cancer patients, 37–38
Smoking
of cannabis
and respiratory effects, 253–54
and risk of coronary heart disease, 180, 183
and exercise, 393, 397, 404–6
as predisposing factor
in postphlebitic syndrome, 95, 100
Sodium
restriction of
in congestive heart failure treatment, 169, 171–73, 175
role in sweating, 433, 435–36, 448
Sodium bicarbonate
and kidney stone dissolution, 363–64
Sodium chloride
and sweat composition, 445–48
Sodium intake
in renal failure in children, 22–24
Sodium-potassium adenosine triphosphatase (Na/K-ATPase)
role in normal sweating, 431–32, 435–36
Sodium salicylate
effect on prostaglandin synthesis, 6–11
Sodium valproate
in febrile seizure prevention, 466
Somatosensory evoked potentials (SEP)
clinical applications of, 478–80, 484
Somatostatin
and growth hormone secretion, 284
Somatotropin
historical background of, 520
Spectinomycin
in gonorrhea treatment, 345
Spermatogenesis
suppression of
by hormone agonists, 474, 496
SRSA (Slow-reacting substance of anaphylaxis)
see Leukotrienes
Stanozolol
in treatment of postphlebitic syndrome, 101
Staphylococci
as cause of endocarditis, 413–14, 1416, 422–23, 426
Starch block gel electrophoresis
in growth hormone studies, 522, 525
Steroids
in aneurysm treatment, 371
see Adrenal steroids
Steroid secretion
effects of hormonal agonists on, 491–98
Steroid therapy
and progressive renal failure in children, 28, 31
Stomach
mechanism and disorders of
see Gastric emptying
Streptococci
as cause of endocarditis, 413–14, 416, 418–20
Streptokinase
in treatment of thrombosis, 94
Streptomycin
in endocarditis therapy, 413, 148, 420
in gonorrhea treatment, 345
Stress
as precipitating Graves' disease, 278
Struvite
see Kidney stones
Subarachnoid hemorrhage
surgical treatment of, 367–74
aneurysms, 371–74
arteriovenous malformations, 370–71
diagnosis, 368–70
management, 370–71
natural history of, 370

Substance abuse
see Cannabis
Sucrose
and dietary fat
in coronary heart disease, 182
Suicide
thoughts of
and depressive mood assessment, 236
Sulfisoxazole
in gonorrhea treatment, 344–45
Sulfonamide-pyrimethamine combinations
in malaria treatment, 322, 325–26
Sulfonamides
in urethritis treatment, 347
Suppressor cell function
in immunoregulation in bowel disease, 198
Surgery
use of evoked potentials during, 484–85
see Subarachnoid hemorrhage
Surgical dressings
and dermatologic infection risk, 216
Sweating, 429–48
anhidrosis, 441–44
central control, 434
composition of sweat, 44–48
congenital abnormalities, 444
emotional, 437–39
gland stimulation, 434–35
gustatory, 439–40
hyperhidrosis, 437–41
neural lesions, 441–43
normal, 430–42
physical damage, 443
reabsorption, 436–37
secretion, 435–36
structural abnormalities, 432–34
Systemic lupus erythematosus
and C5 deficiency, 51
and Graves' disease, 268
and plasma exchange therapy, 76, 80, 84–85

T

Tannins
role in iron absorption, 59
Tartaric acid
role in iron absorption, 59
Tea
and reduction of iron absorption, 59
Temperature control
and sweating, 430, 434, 440–41, 444
Teprotide
in congestive heart failure treatment, 174–75
Teratogenicity
of marijuana, 255
Testosterone secretion
and hormone agonists, 492–95
Tetracyclines
in gonorrhea treatment, 342–43, 347, 353
in malaria treatment, 325, 328–29
δ-9-Tetrahydrocannabinol (THC)
see Cannabis
Thalassemia major
and iron absorption, 64
THAM-E
in kidney stone dissolution, 359, 363–64, 366
THC
see Cannabis
Thermoregulation
disorders of
see Sweating
Thiazide diuretics
in heart failure
and diabetes, 166
Thinking disorders
assessment of, 42
in cancer patients
see Cognitive defects
Thoracic duct drainage
as antirejection therapy
in kidney transplants, 31–32
Thought disorder
cannabis-induced, 250–51
Thrombophlebitis
see Postphlebitic syndrome
Thromboxane
in diabetes mellitus, 2–3
in postphlebitic syndrome, 97
Thrombocytopenic purpura
and plasma exchange therapy, 72, 79, 82 85
Thyroid
see Hyperthyroidism; Pseudohypoparathyroidism
Thyroid-stimulating hormone (TSH)
deficiency
and growth hormone deficiency, 535
and hyperthyroidism, 267–68, 271–73, 276–78
and tumor management, 284
Thyrotoxicosis
antibody analysis in, 15–17
Thyrotropin
resistance to
and pseudohypoparathyroidism, 261
Thyrotropin-binding inhibitory immunoglobulin (TBII)
and autoimmunity in hyperthyroidism, 268, 272
Thyrotropin-releasing hormone (TRH)
in Graves' disease, 271
and pituitary tumor management, 284–85
Tissue typing
and transplant donation, 30
see HLA
Toxins
and plasma exchange therapy, 80–81
Training effect
of exercise
and coronary heart disease, 392, 399, 401–2, 404
Transferrin
and iron absorption, 62–63
Transfusion therapy
in renal therapy for children, 30–31
Transplant
renal
see Renal transplant
survival
see Kidney transplant survival
Trauma
assessment of
by evoked potential studies, 484
Tricyclic antidepressants
in cancer
and cognitive deficits, 41
Triglycerides
and gastric emptying rates, 226
Trimethoprim-sulfamethoxazole
in urethritis treatment, 347, 353
Tumors
steroid-sensitive
see Prostate cancer
Tumor therapy
with antibodies, 107–15
antigenic modulation, 111
antiidiotype antibody, 113
bone marrow transplants, 113–14
clinical studies, 108–9
future prospects, 114–15
mouse monoclonal antibodies, 110–11
problems encountered in, 108–9, 114
therapeutic effects, 111–12
toxicity, 110

Turcot's syndrome
and risk of colorectal cancer, 504
Turner syndrome
and growth hormone deficiency, 535

U

Ulceration
in phlebitis, 95, 98, 101
Ulcerative colitis
and risk of colorectal cancer, 503, 505–6
see also Colitis; Inflammatory bowel disease
Ultrasound
in thrombosis and phlebitis, 99–100
Ureaplasma urealyticum
in urethral infections, 337, 344, 348
Uremia
and renal therapy for children, 26
Urethral infections, 337–54
gonorrhea, 337–44
nongonococcal, 344–48
urethritis in women, 348–54
Urethritis
nongonococcal, 344–48
clinical features, 345–46
diagnosis, 346–47
etiology, 344–45
recurrent, 347–48
treatment, 347
in women, 348–54
diagnosis, 351–53
etiology and pathogenesis, 348–51
treatment, 353–54
see also Gonorrhea
Uric acid calculi
percutaneous dissolution of, 363–64
Urokinase
in treatment of thrombosis, 94

V

Vaginitis
and urethritis, 349–50, 352
Vancomycin
in endocarditis therapy, 416, 420–21, 424
Varicella-zoster virus (VZV)
and infection risk
in compromised hosts, 211–12
Varicose veins
and phlebitis, 94
Vascular disease
role of diet in
see Atherosclerosis
Vasodilator therapy
in congestive heart failure treatment, 169, 172–73, 176
in right ventricular infarction, 386
Vasospasm
and subarachnoid hemorrhage, 373–74
Venereal disease
urethral infections
see Gonorrhea; Urethral infections; Urethritis
Venous occlusion
see Postphlebitic syndrome
Vessel disease
in children
and renal therapy, 25
Vincristine
and cognitive defects, 39, 43
Viral infection
as cause of diabetes mellitus, 1, 13–14, 16
nosocomial spread of
see Respiratory syncytial virus
of the skin
of compromised host, 210–12
Visual evoked potentials
clinical application, 474–78, 484
Vitamin D
deficiency
and pseudohypoparathyroidism, 263–64
interactions with phenobarbital, 466

W

Warfarin
in anticoagulant therapy, 102
Warts
as viral infection
in compromised hosts, 210–11
Wechsler Intelligence Scales for Children (WISC)
in febrile seizure studies, 461
Women
heart failure and diabetes in, 161–66
iron needs of, 56, 63–64
urethritis in, 348–54
World Health Organization
Expert Committee on Diabetes
and diabetes diagnosis criteria, 297–98, 301–5, 307–8

Annual Review of Medicine
Volume 34, 1983

CONTENTS

[Note: Titles of chapters in Volumes 30–34 are arranged by category on pages 571–77.]

PROSTAGLANDINS, GLUCOSE HOMEOSTASIS, AND DIABETES MELLITUS, *R. Paul Robertson* 1

ETIOLOGY OF TYPE I DIABETES MELLITUS: Heterogeneity and Immunological Events Leading to Clinical Onset, *D. Doniach, G. F. Bottazzo, and A. G. Cudworth* 13

MANAGEMENT OF CHILDREN WITH PROGRESSIVE RENAL FAILURE, *John T. Herrin* 21

CHEMOTHERAPY AND COGNITIVE DEFECTS IN CANCER PATIENTS, *Peter M. Silberfarb* 35

INFECTIONS AND HYPOCOMPLEMENTEMIA, *Ira M. Goldstein and Shelley R. Marder* 47

IRON ABSORPTION, *Robert W. Charlton and Thomas H. Bothwell* 55

APPLICATIONS AND LIMITATIONS OF HEMAPHERESIS, *Arthur J. Silvergleid* 69

PATHOGENESIS OF THE POSTPHLEBITIC SYNDROME, *Peter Jacobs* 91

BIOLOGICAL AND CLINICAL IMPLICATIONS OF LYMPHOCYTE HYBRIDOMAS: Tumor Therapy with Monoclonal Antibodies, *Ronald Levy and Richard A. Miller* 107

IDENTIFICATION AND SIGNIFICANCE OF CELL MARKERS IN LEUKEMIA AND LYMPHOMA, *Roger A. Warnke and Michael P. Link* 117

IMMUNOLOGICAL FACTORS INFLUENCING RENAL GRAFT SURVIVAL, *G. Opelz and V. Lenhard* 133

INSULIN RECEPTORS AND INSULIN RESISTANCE, *Jeffrey S. Flier* 145

CONGESTIVE HEART FAILURE IN THE DIABETIC, *Timothy J. Regan* 161

DRUG SUPPRESSION OF THE ANGIOTENSIN SYSTEM IN CONGESTIVE HEART FAILURE, *Jay M. Sullivan* 169

(continued)

CONTENTS (*continued*)

THE ROLE OF DIET IN THE ETIOLOGY AND TREATMENT OF ATHEROSCLEROSIS, *Paul Samuel, Donald J. McNamara, and Joseph Shapiro* 179

IMMUNOREGULATORY MECHANISMS IN NONSPECIFIC INFLAMMATORY BOWEL DISEASE, *R. G. Strickland and D. P. Jewell* 195

DERMATOLOGIC MANIFESTATIONS OF INFECTION IN THE COMPROMISED HOST, *John S. Wolfson, Arthur J. Sober, and Robert H. Rubin* 205

MECHANISMS AND DISORDERS OF GASTRIC EMPTYING, *J. N. Hunt* 219

THE DIAGNOSIS AND TREATMENT OF MAJOR DEPRESSIVE DISORDER IN CHILDHOOD, *Joaquim Puig-Antich and Burt Weston* 231

CANNABIS AND HEALTH, *Reese T. Jones* 247

PSEUDOHYPOPARATHYROIDISM, *Cornelis Van Dop and Henry R. Bourne* 259

PATHOGENESIS OF HYPERTHYROIDISM, *Inder J. Chopra and David H. Solomon* 267

THE MEDICAL MANAGEMENT OF HORMONE-SECRETING TUMORS OF THE PITUITARY, *J. A. H. Wass and G. M. Besser* 283

THE DIAGNOSIS OF DIABETES: New International Classification and Diagnostic Criteria, *Peter H. Bennett* 295

THE NOSOCOMIAL SPREAD OF RESPIRATORY SYNCYTIAL VIRAL INFECTIONS, *Caroline Breese Hall* 311

FALCIPARUM MALARIA: The Urgent Need for Safe and Effective Drugs, *Karl H. Rieckmann* 321

URETHRAL INFECTIONS IN MEN AND WOMEN, *Edward S. Wong and Walter E. Stamm* 337

PERCUTANEOUS DISSOLUTION OF RENAL CALCULI, *Stephen P. Dretler and Richard C. Pfister* 359

SUBARACHNOID HEMORRHAGE, *Roberto C. Heros and Nicholas T. Zervas* 367

RIGHT VENTRICULAR INFARCTION, *Robert Roberts and Alon T. Marmor* 377

EXERCISE AND CORONARY HEART DISEASE, *Nancy A. Rigotti, Gregory S. Thomas, and Alexander Leaf* 391

(*continued*)

ANTIBIOTIC TREATMENT OF INFECTIVE ENDOCARDITIS, *W. R. Wilson and J. E. Geraci* 413

SWEATING AND ITS DISORDERS, *Paul M. Quinton* 429

THE NATURAL HISTORY OF FEBRILE SEIZURES, *Deborah G. Hirtz and Karin B. Nelson* 453

SENSORY EVOKED POTENTIALS: Clinical Applications in Medicine, *Leslie J. Dorfman* 473

SUPERACTIVE GONADOTROPIN-RELEASING HORMONE AGONISTS, *Ronald S. Swerdloff and David Heber* 491

EARLY DIAGNOSIS OF COLORECTAL CANCER, *Robert B. Fath, Jr., and Sidney J. Winawer* 501

STRUCTURAL VARIANTS OF HUMAN GROWTH HORMONE: Biochemical, Genetic, and Clinical Aspects, *Rajender K. Chawla, John S. Parks, and Daniel Rudman* 519

INDEXES

Subject Index 549
Cumulative Index of Contributing Authors, Volumes 30–34 568
Cumulative Index of Chapter Titles, Volumes 30–34 571

Special Announcement: New From Annual Reviews

Volume 1 of the *Annual Review of Immunology* (Editors: William E. Paul, C. Garrison Fathman, and Henry Metzger) will be published in April, 1983.

Some Historical and Modern Aspects of Amino Acids, Fermentations and Nucleic Acids, Proceedings of a Symposium held in St. Louis, Missouri, June 3, 1981, edited by Esmond E. Snell. Published October, 1982. 141 pp.; softcover; $10.00 USA/$12.00 elsewhere, postpaid per copy